About
MobileODT develops optical diagnostic devices and software services designed for early cancer detection and a range of other medical purposes. The company is creating advanced optical technology components to turn smartphones into easy-to-use mobile point-of-care tools to help detect cancer and capture a range of biomedical images for diagnostic and other analytical purposes.
Mobile ODT also develops intuitive app-based programs to operate its devices and connect them to a cloud-based software platform. The platform will enable immediate remote consultation with experts for improved case management and easy integration with a range of emerging electronic health record programs.
The company’s EVA COLPO is an FDA-cleared, internet-connected portable colposcope that is as simple to use as a mobile phone. The device combines advanced hardware with integrated software to serve a variety of clinical needs.
The EVA SANE is a secure and easy-to-use forensic documentation system for fast examinations. It combines the capabilities of a video colposcope and a digital camera to enable both full-body and external body cavity image and video capture. The EVA WELL is an FDA-cleared and HIPAA-compliant digital visualization tool for gynecologic exams.
Funding history · 3 rounds · $22.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is MobileODT's primary focus?
- MobileODT develops optical diagnostic devices and software services for early cancer detection and other medical purposes, primarily focusing on AI-based cervical cancer screening solutions.
- When was MobileODT founded and where is its headquarters located?
- MobileODT was founded in October 2012 and is headquartered in Tel Aviv-Yafo, Israel, with an additional office in New York, USA.
- What is MobileODT's total funding raised to date?
- MobileODT has raised a total of $22,475,000 in funding, according to startupim data.
- Which investors participated in MobileODT's Series C funding round?
- MobileODT completed a $4 million Series C round in August 2020, with OrbiMed as the lead investor, alongside Tristel, Tara Health Foundation, and Laerdal Global.
- What is the EVA COLPO device?
- The EVA COLPO is an FDA-cleared, internet-connected portable colposcope developed by MobileODT, designed for various clinical needs and as simple to use as a mobile phone.
- What recognition did MobileODT receive in May 2022?
- In May 2022, MobileODT won the MedTech Breakthrough Imaging Award.
- What significant development did MobileODT announce in January 2022?
- In January 2022, MobileODT announced the release of a next-generation AI algorithm for cervical cancer screening.
- What was MobileODT's involvement in India in December 2021?
- In December 2021, MobileODT participated in India's largest cervical cancer screening program.
- What grant did MobileODT receive in January 2021?
- In January 2021, MobileODT was awarded a $2.3 million National Cancer Institute (NCI) SBIR grant.
- What was the subject of a news report involving MobileODT in May 2020?
- In May 2020, a news report from The Times of Israel discussed a medical tech dispute involving MobileODT, shedding light on the power balance between entrepreneurs and investors.